Figure 1.

H-RT on 4T1-derived subcutaneous tumor combined with L-TBI. (A) Experimental groups were treated as represented in the timeline. Immunocompetent mice were injected s.c. with syngeneic 4T1 cells (1 × 10⁵) into the right (primary tumor) and left (secondary tumor) flank, respectively. H-RT was administered locally to the primary tumor from day 17 to 19, and L-TBI was administered on day 14. Primary and secondary tumor volumes were measured. On day 24, mice were sacrificed and tumors weighed. (B) Tumor growth of primary tumors (right panel) and secondary tumor (left panel) in mice treated with control (black line), H-RT (yellow line), L-TBI (red line), and combination of the H-RT and L-TBI (blue line). Data are the mean ± SE of 12 mice/group. (C) Primary tumor weight (right panel) and secondary tumor weight (left panel) on day 24 (n = 8 mice/group). (D) Overall survival of the tumor bearing mice of different treatment groups (n = 12 mice/group). (E) Representative pre- and post-treatment 18F-FDG PET images of tumor-bearing mice in control, and treatments groups (L-TBI, H-RT, H-RT+L-TBI; n = 5 mice/group). (F) Tumor/muscle ratio of primary (right panel) and secondary (left panel) tumor in the pre-treatment (on day 13) and post-treatment (on day 24) period (n = 5 mice/group). The experiment has been repeated in similar result (^*P < 0.05, ^**P < 0.01, ^*** P < 0.001 and NS = not significant).